beta-Amyloid Antibody (1-40), pAb, Rabbit

USA

This antibody is specific to human β, -amyloid 1-40. Weak cross-reactivity is observed with human β, -amyloid 1-42.

A number of mutations, identified in the gene encoding the beta-amyloid precursor protein (betaAPP), have been linked to early-onset Familial Alzheimers Disease. betaAPP is cleaved sequentially by the proteolytic enzymes beta-secretase and gamma-secretase to produce beta-amyloid (Abeta) peptides with the Abeta1-42(43) and the Abeta1-40 forms being the most prevalent. Secreted Abeta peptides can bind to scavenger receptors and the receptor for advanced glycation endproducts. Abeta peptides are degraded either via a reuptake mechanism followed by endosomal degradation or by an extracellular insulin-degrading enzyme. Extracellular accumulation of Abeta leads to formation of aggregates, fibrils, and eventually amyloid deposits called neuritic plaques, a hallmark of Alzheimer’s disease. beta-amyloid antibodies and peptides have been developed as tools for elucidating the biology of Alzheimers disease. The rabbit anti-beta-amyloid 1-40 antibody is developed in rabbit using a synthetic peptide corresponding to amino acids 1-40 of beta-amyloid conjugated to KLH. This polyclonal antibody is highly purified from rabbit antiserum by immunoaffinity chromatography and is supplied as a 100 ul aliquot at a concentration of 1 mg/ml in PBS, pH7.4, containing 0.02% sodium azide.

Immunoaffinity chromatography